Dr. Clara I. Restrepo, MD

Dr. Restrepo practices at National Jewish Health in Denver, Colorado, part of National Jewish Health.

Dr. Restrepo's NPI, 1073640017, was assigned on February 27, 2007. Dr. Restrepo graduated from LSU Health Sciences Center New Orleans - School of Medicine in 1990. Dr. Restrepo holds Colorado license 36246.

Dr. Restrepo's primary practice is National Jewish Health, at 1400 Jackson St, Denver, CO 80206 in Denver County. The practice phone is (303) 388-4461.

Dr. Restrepo's primary practice is National Jewish Health in Denver, Colorado, part of National Jewish Health. The medical group on file is Denver Health. Dmand AI also links Dr. Restrepo to 1 more medical group, named with a free account. Dr. Restrepo's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Restrepo practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Restrepo's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Restrepo is board certified in sleep medicine by the American Board of Family Medicine. Dmand AI has Dr. Restrepo's licenses on file in 2 states: Colorado and Louisiana.

CMS data shows 238 Medicare services from Dr. Restrepo across 6 procedure codes in 2024, for 205 Medicare patients. Medicare paid $24,686 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 205 Medicare patients who saw Dr. Restrepo in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Restrepo's median patient age at 70, with 56% women.

In 2024, Dr. Restrepo wrote 488 Medicare Part D claims for 103 patients. 75% of them were for generic drugs. CMS names the drug for 418 of them, across 13 drugs with 11 or more claims each, at $68,736 in total drug cost. In 2023, CMS named 428 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Restrepo for performance year 2024, reported as part of a group. Dr. Restrepo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Restrepo as offering telehealth.

Dmand AI links 6 papers to Dr. Restrepo, published from 2020 to 2025. The most frequent topics are Sarcoidosis, Pulmonary, Bronchoalveolar Lavage Fluid and Disease Progression. Dr. Restrepo has published most often in bioRxiv. Dr. Restrepo's most frequent co-authors are Lisa M. Maier, MD, Shu-Yi Liao, DSC, MD, MPH, MS and Nancy Lin, MD.

CMS Open Payments shows 9 general payments to Dr. Restrepo from 7 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $117.

Dmand AI lists 1 award for Dr. Restrepo, most recently CMS Stage 1 2012 in 2011.

Dr. Restrepo graduated from LSU Health Sciences Center New Orleans - School of Medicine in 1990.

Dr. Restrepo is in network with 15 carriers, including Blue Cross Blue Shield of Michigan, HCSC and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.